Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of the Beta-blocker Propranolol Alone and With Chemotherapy in Patients Receiving Neoadjuvant Treatment for Newly Diagnosed Breast Cancer

Trial Profile

A Study of the Beta-blocker Propranolol Alone and With Chemotherapy in Patients Receiving Neoadjuvant Treatment for Newly Diagnosed Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2019

At a glance

  • Drugs Propranolol (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Pertuzumab; Taxanes; Trastuzumab
  • Indications Breast cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 28 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 11 Dec 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top